Long-term echocardiographic and cardioscintigraphic effects of growth hormone treatment in adults with Prader-Willi syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 5, 2015, Pages 2106-2114

  Marzullo, Paolo ^a,c   Marcassa, Claudio ^b   Minocci, Alessandro ^a   Campini, Riccardo ^b   Eleuteri, Ermanno ^b   Gondoni, Luca Alessandro ^a   Aimaretti, Gianluca ^c   Sartorio, Alessandro ^a   Scacchi, Massimo ^a   Grugni, Graziano ^a  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^b IRCCS   (Italy)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; DOBUTAMINE; GROWTH HORMONE; SOMATOMEDIN C; HUMAN GROWTH HORMONE;

ABDOMINAL FAT; ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CARDIOVASCULAR RESPONSE; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ENDOCRINE SYSTEM; FAT FREE MASS; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FILLING PRESSURE; HEART LEFT VENTRICLE MASS; HEART RIGHT VENTRICLE EJECTION FRACTION; HEART SCINTISCANNING; HUMAN; LEAN BODY WEIGHT; LONGITUDINAL STUDY; MALE; METABOLIC PARAMETERS; OBESITY; OPEN STUDY; PRADER WILLI SYNDROME; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCINTIANGIOGRAPHY; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; WHOLE BODY SCINTISCANNING; BODY COMPOSITION; DRUG EFFECTS; ECHOGRAPHY; HEART; PRADER-WILLI SYNDROME; SCINTISCANNING; YOUNG ADULT;

ADULT; BODY COMPOSITION; BODY MASS INDEX; ECHOCARDIOGRAPHY; FEMALE; HEART; HUMAN GROWTH HORMONE; HUMANS; MALE; PRADER-WILLI SYNDROME; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84929353299     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-1063     Document Type: Article

References (47)

1. Höybye C, Hilding A, Jacobsson H, Thorén. M. Metabolic profile and body composition in adults with Prader-Willi syndrome and severe obesity. J Clin Endocrinol Metab. 2002;87:3590-3597.
2. Cassidy SB, Schwartz S, Miller JL, Driscoll DJ. Prader-Willi syndrome. Genet Med. 2012;14:10-26.
3. Grugni G, Crinò A, Bedogni G, et al. Metabolic syndrome in adult patients with Prader-Willi syndrome. Nutr Metab Cardiovasc Dis. 2013;23:1134-1140.
4. Grugni G, Marzullo P, Ragusa L, et al. Impairment of GH responsiveness to combined GH-releasing hormone and arginine administration in adult patients with Prader-Willi syndrome. Clin Endocrinol (Oxf). 2006;65:492-499.
5. van Nieuwpoort IC, Sinnema M, Castelijns JA, Twisk JW, Curfs LM, Drent ML. The GH/IGF-I axis and pituitary function and size in adults with Prader-Willi syndrome. Horm Res Paediatr. 2011;75:403-411.
6. Theodoro MF, Talebizadeh Z, Butler MG. Body composition and fatness patterns in Prader-Willi syndrome: comparison with simple obesity. Obesity (Silver Spring). 2006;14:1685-1690.
7. Isgaard J, Tivesten A, Friberg P, Bengtsson BA. The role of the GH/IGF-I axis for cardiac function and structure. Horm Metab Res. 1999;31:50-54.
8. Grugni G, Marostica E, Crinò A, Marzullo P, De Nicolao G, Sartorio A. Deconvolution-based assessment of pituitary GH secretion stimulated with GHRH+ arginine in Prader-Willi adults and obese controls. Clin Endocrinol (Oxf). 2013;79:224-231.
9. Deal CL, Tony M, Höybye C, Allen DB, Tauber M, Christiansen JS. Growth Hormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J Clin Endocrinol Metab. 2013;98:E1072-E1087.
10. Carrel AL, Myers SE, Whitman BY, Eickhoff J, Allen DB. Long-term growth hormone therapy changes the natural history of body composition and motor function in children with Prader-Willi syndrome. J Clin Endocrinol Metab. 2010;95:1131-1136.
11. Bakker NE, Kuppens RJ, Siemensma EP, et al. Eight years of growth hormone treatment in children with Prader-Willi syndrome: maintaining the positive effects. J Clin Endocrinol Metab 2013;98:4013-4022.
12. Coupaye M, Lorenzini F, Lloret-Linares C, et al. Growth hormone therapy for children and adolescents with Prader-Willi syndrome is associated with improved body composition and metabolic status in adulthood. J Clin Endocrinol Metab. 2013;98:E328-E335.
13. Höybye C. Five-years growth hormone (GH) treatment in adults with Prader-Willi syndrome. Acta Paediatr. 2007;96:410-413.
14. Sode-Carlsen R, Farholt S, Rabben KF, et al. Growth hormone treatment in adults with Prader-Willi syndrome: the Scandinavian study. Endocrine. 2012;41:191-199.
15. Lafortuna CL, Minocci A, Capodaglio P, et al. Skeletal muscle characteristics and motor performance after 2-year growth hormone treatment in adults with Prader-Willi syndrome. J Clin Endocrinol Metab. 2014;99:1816-1824.
16. Oto Y, Tanaka Y, Abe Y, et al. Exacerbation of BMI after cessation of growth hormone therapy in patients with Prader-Willi syndrome. Am J Med Genet A. 2014;164A:671-675.
17. Marcus KA, van Alfen-van der Velden JA, Otten BJ, et al. Cardiac evaluation in children with Prader-Willi syndrome. Acta Paediatr. 2012;101:e225-e231.
18. Patel S, Harmer JA, Loughnan G, Skilton MR, Steinbeck K, Celermajer DS. Characteristics of cardiac and vascular structure and function in Prader-Willi syndrome. Clin Endocrinol (Oxf). 2007;66:771-777.
19. Marzullo P, Marcassa C, Campini R, et al. The impact of growth hormone/insulin-like growth factor-I axis and nocturnal breathing disorders on cardiovascular features of adult patients with Prader-Willi syndrome. J Clin Endocrinol Metab. 2005;90:5639-5646.
20. Marzullo P, Marcassa C, Campini R, et al. Conditional cardiovascular response to growth hormone therapy in adult patients with Prader-Willi syndrome. J Clin Endocrinol Metab. 2007;92:1364-1371.
21. Biller BM, Samuels MH, Zagar A, et al. Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab. 2002;87:2067-2079.
22. Schmidt H, Pozza SB, Bonfig W, Schwarz HP, Dokoupil K. Successful early dietary intervention avoids obesity in patients with Prader-Willi syndrome: a ten-year follow-up. J Pediatr Endocrinol Metab. 2008;21:651-655.
23. Schrander-Stumpel CT, Curfs LM, Sastrowijoto P, Cassidy SB, Schrander JJ, Fryns JP. Prader-Willi syndrome: causes of death in an international series of 27 cases. Am J Med Genet A. 2004;124A:333-338.
24. Vogels A, Van Den Ende J, Keymolen K, et al. Minimum prevalence, birth incidence and cause of death for Prader-Willi syndrome in Flanders. Eur J Hum Genet. 2004;12:238-240.
25. Nagai T, Obata K, Tonoki H, et al. Cause of sudden, unexpected death of Prader-Willi syndrome patients with or without growth hormone treatment. Am J Med Genet A. 2005;136:45-48.
26. Sinnema M, Maaskant MA, van Schrojenstein Lantman-de Valk HM, et al. Physical health problems in adults with Prader-Willi syndrome. Am J Med Genet A. 2011;155A:2112-2124.
27. Grugni G, Crinò A, Bosio L, et al. The Italian National Survey for Prader-Willi syndrome: an epidemiologic study. Am J Med Genet A. 2008;146A:861-872.
28. Greenswag LR. Adults with Prader-Willi syndrome: a survey of 232 cases. Dev Med Child Neurol. 1987;29:145-152.
29. Butler JV, Whittington JE, Holland AJ, Boer H, Clarke D, Webb T. Prevalence of, and risk factors for, physical ill-health in people with Prader-Willi syndrome: a population-based study. Dev Med Child Neurol. 2002;44:248-255.
30. Whittington JE, Holland AJ, Webb T, Butler J, Clarke D, Boer H. Population prevalence and estimated birth incidence and mortality rate for people with Prader-Willi syndrome in one UK health region. J Med Genet. 2001;38:792-798.
31. Colao A, Marzullo P, Di Somma C, Lombardi G. Growth hormone and the heart. Clin Endocrinol (Oxf). 2001;54:137-154.
32. Maison P, Chanson P. Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis. Circulation. 2003;108:2648-2652.
33. Hauffa BP, Knaup K, Lehmann N, Neudorf U, Nagel B. Effects of growth hormone therapy on cardiac dimensions in children and adolescents with Prader-Willi syndrome. Horm Res Paediatr. 2011;75:56-62.
34. Saccà L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr Rev. 1994;15:555-573.
35. Pomara C, D'Errico S, Riezzo I, de Cillis GP, Fineschi V. Sudden cardiac death in a child affected by Prader-Willi syndrome. Int J Legal Med. 2005;119:153-157.
36. Castner DM, Rubin DA, Judelson DA, Haqq AM. Effects of adiposity and Prader-Willi Syndrome on postexercise heart rate recovery. J Obes. 2013;2013:384167.
37. Purtell L, Jenkins A, Viardot A, et al. Postprandial cardiac autonomic function in Prader-Willi syndrome. Clin Endocrinol (Oxf). 2013;79:128-133.
38. Arens R, Gozal D, Burrell BC, et al. Arousal and cardiorespiratory responses to hypoxia in Prader-Willi syndrome. Am J Respir Crit Care Med. 1996;153:283-287.
39. Kawano H, Ikeda T, Shimazaki K, et al. Successful treatment of heart failure in an adult patient with Prader-Willi syndrome. Intern Med. 2013;52:771-776.
40. Davies PS. Body composition in Prader-Willi syndrome: assessment and effects of growth hormone administration. Acta Paediatr Suppl. 1999;88:105-108.
41. Lindgren AC, Ritzén EM. Five years of growth hormone treatment in children with Prader-Willi syndrome. Swedish National Growth Hormone Advisory Group. Acta Paediatr Suppl. 1999;88:109-111.
42. Carrel AL, Myers SE, Whitman BY, Allen DB. Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study. J Clin Endocrinol Metab. 2002;87:1581-1585.
43. Höybye C, Hilding A, Jacobsson H, Thorén M. Growth hormone treatment improves body composition in adults with Prader-Willi syndrome. Clin Endocrinol (Oxf). 2003;58:653-661.
44. Reus L, van Vlimmeren LA, Staal JB, Otten BJ, Nijhuis-van der Sanden MW. The effect of growth hormone treatment or physical training on motor performance in Prader-Willi syndrome: a systematic review. Neurosci Biobehav Rev. 2012;36:1817-1638.
45. Mogul HR, Lee PD, Whitman BY, et al. Growth hormone treatment of adults with Prader-Willi syndrome and growth hormone deficiency improves lean body mass, fractional body fat, and serum triiodothyronine without glucose impairment: results from the United States multicenter trial. J Clin Endocrinol Metab. 2008;93:1238-1245.
46. Olarescu NC, Jørgensen AP, Godang K, Jurik AG, Frøslie KF, Bollerslev J. Dual-energy x-ray absorptiometry is a valid method to estimate visceral adipose tissue in adult patients with Prader-Willi syndrome during treatment with growth hormone. J Clin Endocrinol Metab. 2014;99:E1727-E1731.
47. Gondoni LA, Vismara L, Marzullo P, Vettor R, Liuzzi A, Grugni G. Growth hormone therapy improves exercise capacity in adult patients with Prader-Willi syndrome. J Endocrinol Invest. 2008;31:765-772.